Drugs / Aroxybutynin
Aroxybutynin
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT04631107 | Dec 2020 → May 2021 | obstructive sleep apnea syndrome | Apnimed | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06566820 | Jul 2024 → Jun 2026 overdue | obstructive sleep apnea syndrome | Apnimed | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT05813275 | Sep 2023 → Mar 2025 | obstructive sleep apnea syndrome | Apnimed | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04580394 Comparator | Oct 2020 → May 2021 | obstructive sleep apnea syndrome | Apnimed | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Aroxybutynin | “The current study is with aroxybutynin (AD109), a new enantiomerically pure form of oxybutynin with better safety profile compared to racemic oxybutynin.” PMID 35975547 ↗ Dec 20222“Aroxybutynin and atomoxetine (AD109) for obstructive sleep apnea: a randomized” PMID 42148495 ↗ Jul 2026 |
| Known as | Aroxybutynin component of ad-109 | ChEMBL registry synonym — accepted as the source's own label CHEMBL185434 ↗ |
| Known as | Aroxybutynina | ChEMBL registry synonym — accepted as the source's own label CHEMBL185434 ↗ |
| Known as | Aroxybutynine | ChEMBL registry synonym — accepted as the source's own label CHEMBL185434 ↗ |
| Known as | R-oxybutynin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04580394 ↗ |
| Modality | Small molecule | — CHEMBL185434 ↗ |
| Route | Oral | “Oral administration before bed” NCT04580394 ↗ |